$BCRX
BIOCRYST PHARMACEUTICALS INC

2020 Q3 Form 10-Q Financial Statement

#000117184320005753 Filed on August 07, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q2
Revenue $6.102M $2.871M $1.448M
YoY Change 243.77% 98.27% -88.41%
Cost Of Revenue $1.517M $0.00 $0.00
YoY Change
Gross Profit $4.585M $2.871M $1.448M
YoY Change 158.31% 98.27% -88.41%
Gross Profit Margin 75.14% 100.0% 100.0%
Selling, General & Admin $17.20M $13.88M $8.659M
YoY Change 46.53% 60.33% -8.78%
% of Gross Profit 375.03% 483.56% 598.0%
Research & Development $30.25M $27.50M $27.68M
YoY Change 20.4% -0.66% 31.75%
% of Gross Profit 659.65% 957.78% 1911.67%
Depreciation & Amortization $170.0K $180.0K $180.0K
YoY Change -5.56% 0.0% -5.26%
% of Gross Profit 3.71% 6.27% 12.43%
Operating Expenses $47.44M $41.38M $36.34M
YoY Change 28.72% 13.87% 19.14%
Operating Profit -$42.86M -$38.51M -$34.92M
YoY Change 22.13% 10.29% 91.32%
Interest Expense $2.927M $2.918M $3.035M
YoY Change -3.84% -3.86% 38.27%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$46.12M -$38.61M -$37.63M
YoY Change 22.69% 2.6% 103.96%
Income Tax
% Of Pretax Income
Net Earnings -$46.12M -$38.61M -$37.63M
YoY Change 22.67% 2.6% 104.0%
Net Earnings / Revenue -755.74% -1344.72% -2598.69%
Basic Earnings Per Share
Diluted Earnings Per Share -$261.3K -$239.0K -$341.0K
COMMON SHARES
Basic Shares Outstanding 176.6M 154.3M
Diluted Shares Outstanding 176.5K 161.6K 110.3M

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $143.3M $189.4M $92.15M
YoY Change 109.42% 105.54% 14.13%
Cash & Equivalents $96.49M $173.5M $30.76M
Short-Term Investments $46.83M $15.94M $61.39M
Other Short-Term Assets $7.400M $5.200M $6.900M
YoY Change 51.02% -24.64% -25.81%
Inventory $6.241M $5.233M $1.000M
Prepaid Expenses
Receivables $5.422M $3.997M $3.602M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $162.4M $203.8M $103.7M
YoY Change 106.13% 96.53% 11.92%
LONG-TERM ASSETS
Property, Plant & Equipment $7.142M $7.149M $7.551M
YoY Change -4.16% -5.32% -19.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $3.000M $700.0K
YoY Change -97.92%
Other Assets $3.646M $3.720M $4.333M
YoY Change -14.11% -14.15% 415.22%
Total Long-Term Assets $13.79M $10.87M $12.63M
YoY Change 17.89% -13.91% -71.29%
TOTAL ASSETS
Total Short-Term Assets $162.4M $203.8M $103.7M
Total Long-Term Assets $13.79M $10.87M $12.63M
Total Assets $176.2M $214.7M $116.3M
YoY Change 94.72% 84.54% -14.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.62M $9.354M $8.298M
YoY Change 15.19% 12.73% 101.31%
Accrued Expenses $30.46M $24.84M $19.34M
YoY Change 22.07% 28.43% -0.34%
Deferred Revenue
YoY Change
Short-Term Debt $29.90M $29.80M $29.30M
YoY Change 1.36% 1.71% 1.38%
Long-Term Debt Due $19.10M $19.10M $0.00
YoY Change 377.5% -100.0%
Total Short-Term Liabilities $111.8M $102.7M $71.95M
YoY Change 36.03% 42.67% -3.0%
LONG-TERM LIABILITIES
Long-Term Debt $26.90M $31.70M $49.80M
YoY Change -41.52% -36.35% 207.41%
Other Long-Term Liabilities $3.900M $3.800M $3.742M
YoY Change 10.08% 1.55% 3642.0%
Total Long-Term Liabilities $30.80M $35.50M $3.742M
YoY Change 769.32% 848.69% -77.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $111.8M $102.7M $71.95M
Total Long-Term Liabilities $30.80M $35.50M $3.742M
Total Liabilities $142.6M $138.2M $75.69M
YoY Change 66.37% 82.59% -16.36%
SHAREHOLDERS EQUITY
Retained Earnings -$962.9M -$916.8M -$800.4M
YoY Change 14.91% 14.54% 18.59%
Common Stock $1.766M $1.764M $1.104M
YoY Change 59.96% 59.78% 11.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.64M $76.51M -$9.193M
YoY Change
Total Liabilities & Shareholders Equity $176.2M $214.7M $116.3M
YoY Change 94.72% 84.54% -14.86%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$46.12M -$38.61M -$37.63M
YoY Change 22.67% 2.6% 104.0%
Depreciation, Depletion And Amortization $170.0K $180.0K $180.0K
YoY Change -5.56% 0.0% -5.26%
Cash From Operating Activities -$38.26M -$31.04M -$24.50M
YoY Change 38.42% 26.69% 76.26%
INVESTING ACTIVITIES
Capital Expenditures -$170.0K -$70.00K -$90.00K
YoY Change 112.5% -22.22% -50.0%
Acquisitions
YoY Change
Other Investing Activities -$33.89M -$4.860M $22.37M
YoY Change -243.6% -121.73% 1200.58%
Cash From Investing Activities -$34.06M -$4.930M $22.28M
YoY Change -244.87% -122.13% 1356.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.630M 108.2M 410.0K
YoY Change -2536.84% 26287.8% -132.28%
NET CHANGE
Cash From Operating Activities -38.26M -31.04M -24.50M
Cash From Investing Activities -34.06M -4.930M 22.28M
Cash From Financing Activities -4.630M 108.2M 410.0K
Net Change In Cash -76.95M 72.22M -1.810M
YoY Change 1853.05% -4090.06% -86.73%
FREE CASH FLOW
Cash From Operating Activities -$38.26M -$31.04M -$24.50M
Capital Expenditures -$170.0K -$70.00K -$90.00K
Free Cash Flow -$38.09M -$30.97M -$24.41M
YoY Change 38.21% 26.87% 77.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000882796
dei Entity Registrant Name
EntityRegistrantName
BIOCRYST PHARMACEUTICALS INC
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
176565622
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
176429000
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
176429000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
154082000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
154082000
CY2020Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
193000
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
22044000
CY2020Q2 bcrx Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
3511000
CY2019Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
100000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
2188000 USD
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1551000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
15935000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
22054000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3997000 USD
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
0 USD
CY2019Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
341000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
173468000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114172000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
164345000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7149000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22146000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
5233000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
0 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3016000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4422000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
203837000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7347000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3720000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3590000 USD
CY2020Q2 us-gaap Assets
Assets
214706000 USD
CY2019Q4 us-gaap Assets
Assets
175282000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
9354000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13988000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24843000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
21365000 USD
CY2020Q2 us-gaap Interest Payable Current
InterestPayableCurrent
17806000 USD
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
14904000 USD
CY2020Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
715000 USD
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2120000 USD
CY2020Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1096000 USD
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1377000 USD
CY2020Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
19056000 USD
CY2019Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
9020000 USD
CY2020Q2 us-gaap Notes Payable Current
NotesPayableCurrent
29780000 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
29561000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
102650000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
92335000 USD
CY2020Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3834000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3406000 USD
CY2020Q2 us-gaap Line Of Credit
LineOfCredit
31715000 USD
CY2019Q4 us-gaap Line Of Credit
LineOfCredit
41289000 USD
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
1764000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1541000 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
991574000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
877300000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
39000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-916834000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-840628000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
76507000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
38252000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
214706000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
175282000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2871000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1448000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7694000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7335000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1399000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27498000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27681000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57365000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55174000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13883000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8659000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
29748000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14897000 USD
CY2020Q2 us-gaap Royalty Expense
RoyaltyExpense
0 USD
CY2019Q2 us-gaap Royalty Expense
RoyaltyExpense
26000 USD
us-gaap Royalty Expense
RoyaltyExpense
69000 USD
us-gaap Royalty Expense
RoyaltyExpense
113000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
41381000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
36366000 USD
us-gaap Costs And Expenses
CostsAndExpenses
87182000 USD
us-gaap Costs And Expenses
CostsAndExpenses
71583000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-38510000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-34918000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-79488000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-64248000 USD
CY2020Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
2758000 USD
CY2019Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
547000 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
9204000 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
1143000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
2918000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
3035000 USD
us-gaap Interest Expense
InterestExpense
5965000 USD
us-gaap Interest Expense
InterestExpense
5761000 USD
CY2020Q2 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
63000 USD
CY2019Q2 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-223000 USD
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
43000 USD
us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
183000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-38607000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-37629000 USD
us-gaap Net Income Loss
NetIncomeLoss
-76206000 USD
us-gaap Net Income Loss
NetIncomeLoss
-68683000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
130000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-36000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
338000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38618000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37499000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76242000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-68345000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161569000
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110338000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
157862000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
110253000
us-gaap Net Income Loss
NetIncomeLoss
-76206000 USD
us-gaap Net Income Loss
NetIncomeLoss
-68683000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
401000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
357000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
6034000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
8702000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
681000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
596000 USD
bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
104000 USD
bcrx Amortization Of Discount And Premium On Investments
AmortizationOfDiscountAndPremiumOnInvestments
-17000 USD
us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-590000 USD
us-gaap Increase Decrease In Derivative Assets
IncreaseDecreaseInDerivativeAssets
-646000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-18149000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-691000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5233000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-649000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-817000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-84000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1156000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2579000 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2902000 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2897000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1405000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54322000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51499000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
187000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
180000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
15438000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
3018000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
21417000 USD
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
41357000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5792000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38159000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
92848000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
14817000 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
19477000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
798000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
977000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108463000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20454000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
59933000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7114000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
115723000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28275000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
175656000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35389000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
38252000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-37599000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-25000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
266000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2754000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
3648000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-38607000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
532000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
92848000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
14817000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3280000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
76507000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
49235000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-31054000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
208000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
343000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
220000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3317000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
22507000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-37629000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
130000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
414000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5385000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-9193000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
15929000 USD
CY2020Q2 bcrx Available For Sale Debt Securities Accrued Interest
AvailableForSaleDebtSecuritiesAccruedInterest
3000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
-0 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
15935000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
21899000 USD
CY2019Q4 bcrx Available For Sale Debt Securities Accrued Interest
AvailableForSaleDebtSecuritiesAccruedInterest
116000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
40000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
22054000 USD
CY2020Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
3997000 USD
CY2019Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
22146000 USD
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1723000 USD
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3510000 USD
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
1000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2871000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1448000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7694000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
7335000 USD
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
2918000 USD
CY2019Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
3035000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
5965000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
5761000 USD
CY2020Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
341000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
681000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
596000 USD
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14007
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1927
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12963000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2528000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><i><b>Use of Estimates</b></i></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options, and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p>
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6034000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8702000 USD
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
22873000 USD
CY2020Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear
5251000 USD
CY2020Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo
8086000 USD
CY2020Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree
6604000 USD
CY2020Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour
2668000 USD
CY2020Q2 bcrx Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Five
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive
264000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
10000000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
20000000 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20000000 USD
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
50000000 USD
CY2020Q2 bcrx Maximum Aggregate Offering Price
MaximumAggregateOfferingPrice
500000000 USD
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
22044447
CY2020Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4.50
CY2020Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
107665000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P13Y7M6D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.127 pure
us-gaap Operating Lease Expense
OperatingLeaseExpense
935000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
706000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
835000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
749000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
665000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
575000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
568000 USD
CY2020Q2 bcrx Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
7903000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11295000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6365000 USD

Files In Submission

Name View Source Status
0001171843-20-005753-index-headers.html Edgar Link pending
0001171843-20-005753-index.html Edgar Link pending
0001171843-20-005753.txt Edgar Link pending
0001171843-20-005753-xbrl.zip Edgar Link pending
bcrx-20200630.xsd Edgar Link pending
bcrx-20200630_cal.xml Edgar Link unprocessable
bcrx-20200630_def.xml Edgar Link unprocessable
bcrx-20200630_lab.xml Edgar Link unprocessable
bcrx-20200630_pre.xml Edgar Link unprocessable
bcrx20200630_10q.htm Edgar Link pending
bcrx20200630_10q_htm.xml Edgar Link completed
exh103_1.jpg Edgar Link pending
exh103_2.jpg Edgar Link pending
ex_196626.htm Edgar Link pending
ex_196627.htm Edgar Link pending
ex_196628.htm Edgar Link pending
ex_196629.htm Edgar Link pending
ex_196806.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending